<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/ACCAA472-353D-4CD6-814A-04677AE5E921"><gtr:id>ACCAA472-353D-4CD6-814A-04677AE5E921</gtr:id><gtr:name>MRC/UVRI Uganda Research Unit on AIDS</gtr:name><gtr:address><gtr:line1>Uganda Virus Research Institute</gtr:line1><gtr:line2>51-59 Nakiwogo Road, PO box 49</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Uganda</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/ACCAA472-353D-4CD6-814A-04677AE5E921"><gtr:id>ACCAA472-353D-4CD6-814A-04677AE5E921</gtr:id><gtr:name>MRC/UVRI Uganda Research Unit on AIDS</gtr:name><gtr:address><gtr:line1>Uganda Virus Research Institute</gtr:line1><gtr:line2>51-59 Nakiwogo Road, PO box 49</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Uganda</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/626392FD-F63C-452E-B6B3-C5B85ED84586"><gtr:id>626392FD-F63C-452E-B6B3-C5B85ED84586</gtr:id><gtr:firstName>Richard</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>Gilson</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/2A1C6538-03C5-47E3-B2D9-129613E9ECC2"><gtr:id>2A1C6538-03C5-47E3-B2D9-129613E9ECC2</gtr:id><gtr:firstName>Peter</gtr:firstName><gtr:surname>Hughes</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/B5C2A8F2-DAD6-4AEE-BDAC-381A0037E9C5"><gtr:id>B5C2A8F2-DAD6-4AEE-BDAC-381A0037E9C5</gtr:id><gtr:firstName>Pontiano</gtr:firstName><gtr:surname>Kaleebu</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_U950092727"><gtr:id>4DBB612C-6619-47D5-987C-5CFA659FBBA4</gtr:id><gtr:title>Basic Science Programme / Effect of ART on chronic hepatitis B virus infection (substudy of DART trial)</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_U950092727</gtr:grantReference><gtr:abstractText>Infection with the hepatitis B virus (HBV) occurs frequently in Africa. The infection is acquired early in childhood, and later through contaminated blood transfusions, but also through sexual contact with an infected individual. The infection causes liver inflammation. It may heal spontaneously, but many patients become chronically infected. Patients with chronic HBV infection may develop chronic liver disease and liver carcinoma, and remain infectious for others. It is possible that HBV occurs more often among individuals also infected with the human immunodeficiency virus (HIV) that cause AIDS.||Antiretroviral (ARV) drugs that can treat HIV infection also have a suppressive effect on HBV. However it is not known how effective these drugs are in suppressing HBV over time, and to what extent HBV will develop resistance to ARVs. The study will make use of the opportunity of a long lasting HIV trial (the MRC funded international DART Trial in which thousand of patients are treated with ARVs) to study the effects of ARVs on HBV in those patients who are infected with both HIV and HBV.</gtr:abstractText><gtr:technicalSummary>The project aims to determine the prevalence of co-infection with Hepatitis B Virus (HBV) in the DART Trial cohort, and the effects of antiretroviral drugs (tenofovir and lamivudine) on HBV after 1 and 5 years of therapy. The DART Trial is a multicentre trial to compare the effectiveness and safety of different strategies of ART monitoring.||Using archived blood samples from participants in the DART trial, the project will initially determine the HBV status of all patients at the time of enrollment to the DART study. HBV viral load will be measured at baseline and sequentially in all patients identified as HBsAg-positive, with further testing for HBe markers in HBsAg-reactive samples. HBV viral load will be measured on samples from follow-up visits collected at 4, 12, 24, 48 weeks after enrolment and every 48 weeks thereafter until last attendance, or until collection of the last sample before treatment switch. The work is funded by Gilead with co-funding from the MRC.</gtr:technicalSummary><gtr:fund><gtr:end>2011-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-09-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>527888</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Centre for Medical Molecular Virology</gtr:department><gtr:description>Hepatitis B studies</gtr:description><gtr:id>AEEE1466-B1BA-47C7-AF39-3B8CFE78CA84</gtr:id><gtr:impact>Training
Reagents
Abstracts
Staff costs</gtr:impact><gtr:outcomeId>JnmbkfkfoHk-1</gtr:outcomeId><gtr:partnerContribution>Reagents
Staff costs
Publications</gtr:partnerContribution><gtr:piContribution>Protocol development
Running of viral load tests</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Centre for Medical Molecular Virology</gtr:department><gtr:description>Research in Hepatitis B</gtr:description><gtr:id>B3260921-4AED-4823-AAC7-62B3BC775EA3</gtr:id><gtr:impact>Training
Increased capacity to conduct research in hepatitis</gtr:impact><gtr:outcomeId>kRMWMoUuibN-1</gtr:outcomeId><gtr:partnerContribution>Training
Capacity in Hepatitis research</gtr:partnerContribution><gtr:piContribution>Our laboratory performed viral loads and some genotyping</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">MC_U950092727</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>9A8BEDCC-D902-4C9A-8CCF-C974265EA3FB</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>2.4  Surveillance and distribution</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>75</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>